Search research articles
Contact Us
Filters
Showing results (221-230 of 760) with videos related to
Page
of 76
Sort By:
Expert Opinion on Investigational Drugs
|
May 13, 2020
Selatogrel, a novel P2Y<sub>12</sub> inhibitor: a review of the pharmacology and clinical development
Rocco P Milluzzo, Gabriele A Franchina, Davide Capodanno, et al.
JACC. Cardiovascular Interventions
|
April 22, 2022
Reply: Short Duration of DAPT vs De-Escalation After Percutaneous Coronary Intervention: Only These 2 Options?
Claudio Laudani, Antonio Greco, Giovanni Occhipinti, et al.
Expert Opinion on Drug Safety
|
September 19, 2018
Gender differences on benefits and risks associated with oral antithrombotic medications for coronary artery disease
Sara Romano, Sergio Buccheri, Roxana Mehran, et al.
European Heart Journal. Cardiovascular Pharmacotherapy
|
April 21, 2023
Bivalirudin plus a high-dose infusion versus heparin in patients with acute coronary syndrome
Mattia Galli, Giuseppe Gargiulo, Stefano Benenati, et al.
JACC. Cardiovascular Interventions
|
December 10, 2025
Reply: Unveiling the PRODIGY of P2Y<sub>12</sub> Inhibitor Over Aspirin Monotherapy After Acute Coronary Syndrome and Clarification on Trial Classification in Meta-Analysis of Antiplatelet Monotherapy After ACS
Claudio Laudani, Daniele Giacoppo, Antonio Greco, et al.
European Heart Journal. Cardiovascular Pharmacotherapy
|
April 2, 2025
Chronic Coronary Syndrome and New-Onset Atrial Fibrillation or Venous Thromboembolism: How Best to Manage Antithrombotic Therapy Strategies
Andrea Rubboli, Dominick J Angiolillo, Cecilia Becattini, et al.
Clinical Therapeutics
|
November 15, 2011
Impact of a fixed-dose combination of naproxen and esomeprazole magnesium on serum thromboxane B2 inhibition by low-dose aspirin over 5 days in healthy adults: a phase I, randomized, double-blind, placebo-controlled, noninferiority trial
Dominick J Angiolillo, Clara Hwang, Catherine Datto, et al.
JACC. Cardiovascular Interventions
|
May 5, 2022
Reply: Short Duration of DAPT vs De-Escalation After Percutaneous Coronary Intervention for Acute Coronary Syndromes
Antonio Greco, Claudio Laudani, Giovanni Occhipinti, et al.
Expert Opinion on Drug Safety
|
November 12, 2020
Safety and efficacy of P2Y<sub>12</sub> inhibitor monotherapy in patients undergoing percutaneous coronary interventions
Mattia Galli, Davide Capodanno, Felicita Andreotti, et al.
Cardiovascular Diagnosis and Therapy
|
December 1, 2018
Diabetes and antiplatelet therapy: from bench to bedside
Jose R Rivas Rios, Francesco Franchi, Fabiana Rollini, et al.
Page
of 76
Search research articles
Search
Showing results (221-230 of 760) with videos related to
Sort By:
Page
of 76
Expert Opinion on Investigational Drugs
|
May 13, 2020
Selatogrel, a novel P2Y<sub>12</sub> inhibitor: a review of the pharmacology and clinical development
Rocco P Milluzzo, Gabriele A Franchina, Davide Capodanno, et al.
JACC. Cardiovascular Interventions
|
April 22, 2022
Reply: Short Duration of DAPT vs De-Escalation After Percutaneous Coronary Intervention: Only These 2 Options?
Claudio Laudani, Antonio Greco, Giovanni Occhipinti, et al.
Expert Opinion on Drug Safety
|
September 19, 2018
Gender differences on benefits and risks associated with oral antithrombotic medications for coronary artery disease
Sara Romano, Sergio Buccheri, Roxana Mehran, et al.
European Heart Journal. Cardiovascular Pharmacotherapy
|
April 21, 2023
Bivalirudin plus a high-dose infusion versus heparin in patients with acute coronary syndrome
Mattia Galli, Giuseppe Gargiulo, Stefano Benenati, et al.
JACC. Cardiovascular Interventions
|
December 10, 2025
Reply: Unveiling the PRODIGY of P2Y<sub>12</sub> Inhibitor Over Aspirin Monotherapy After Acute Coronary Syndrome and Clarification on Trial Classification in Meta-Analysis of Antiplatelet Monotherapy After ACS
Claudio Laudani, Daniele Giacoppo, Antonio Greco, et al.
European Heart Journal. Cardiovascular Pharmacotherapy
|
April 2, 2025
Chronic Coronary Syndrome and New-Onset Atrial Fibrillation or Venous Thromboembolism: How Best to Manage Antithrombotic Therapy Strategies
Andrea Rubboli, Dominick J Angiolillo, Cecilia Becattini, et al.
Clinical Therapeutics
|
November 15, 2011
Impact of a fixed-dose combination of naproxen and esomeprazole magnesium on serum thromboxane B2 inhibition by low-dose aspirin over 5 days in healthy adults: a phase I, randomized, double-blind, placebo-controlled, noninferiority trial
Dominick J Angiolillo, Clara Hwang, Catherine Datto, et al.
JACC. Cardiovascular Interventions
|
May 5, 2022
Reply: Short Duration of DAPT vs De-Escalation After Percutaneous Coronary Intervention for Acute Coronary Syndromes
Antonio Greco, Claudio Laudani, Giovanni Occhipinti, et al.
Expert Opinion on Drug Safety
|
November 12, 2020
Safety and efficacy of P2Y<sub>12</sub> inhibitor monotherapy in patients undergoing percutaneous coronary interventions
Mattia Galli, Davide Capodanno, Felicita Andreotti, et al.
Cardiovascular Diagnosis and Therapy
|
December 1, 2018
Diabetes and antiplatelet therapy: from bench to bedside
Jose R Rivas Rios, Francesco Franchi, Fabiana Rollini, et al.
Page
of 76